By adopting FDA-endorsed endpoints that are easier to achieve, Dimerix has bolstered the chances of its pivotal kidney drug trial succeeding.

Australia’s S&P/ASX 200 rose 1.4% in June 2025 and gained almost 10% for Q2 CY25 brushing aside geopolitical and macroeconomic concerns.

Robert Friedland's Sunrise Energy Metals has leveraged strong demand to lift a capital raise $7.5 million for its Syerston ...

The ASX 200 closed nearly flat, down 1.2 points. Info tech's rally faltered, but the gold index climbed 1.09pc amid USD decline.

A new report from RFC Ambrian lays out the commanding position China has taken in the gallium market and the outlook for ...

ASX energy smashed it in June, but it was defence stocks like DroneShield, Elsight and archTIS that stole the spotlight.